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Serotyping of Shiga toxin-producing Escherichia coli (STEC) has been contingent upon the availability of antisera.
Here we describe a 7-plex microbead-based immunoassay to simultaneously serotype seven STECs (i.e., belong-
ing to serogroups O26, O45, O103, O111, O121, O145, and O157) by the Luminex xMAP® technology. This tech-
nology presents many advantages: Its multiplexed format (up to 100 analytes) saves time, reagents, and test
sample, and many regulatory agencies currently utilize this platform for other assays. In this study, a total of
seventy-nine STEC strains belonging to the 7 different serogroups of interest were tested. These strains had
been previously serotyped and their serogroup was confirmed by PCR. Except for one strain belonging to the
O111 serogroup, nearly all strains (i.e., 98.7%; 78/79) were correctly identified on the Bio-Plex 100 instrument
in less than 4 h. This newly developed microbead-based immunoassay could be extended to include other
STEC serogroups, virulence factors, and/or bacterial species.
Published by Elsevier B.V.
1. Introduction
Since the active surveillance of non-O157 STEC was implemented in
the United States in 2001 (CDC, 2012), there has been an increase in
number of reported cases of serotypes other than O157 mostly in part
due to enhanced testing for the presence of Shiga toxin (Stx) in outbreak
related strains (Hurd, 2007). Currently non-O157 infections account for
approximately 50% of all confirmed STEC cases in Europe and in the
United States they out number reported O157 cases (Bosilevac and
Koohmaraie, 2011). Yet, the most virulent serotype commonly isolated
in outbreaks in North America is Escherichia coli O157:H7, and is associ-
ated with bloody diarrhea, hemorrhagic colitis (HC), hemorrhagic ure-
mic syndrome (HUS), and thrombotic thrombocytopenic purpura
(Brooks et al., 2005; Willshaw et al., 2000). However, the last 10 years
have produced an increasing number of outbreaks in the United States
attributed to non-O157 STEC which can elicit infections and diseases
similar to E. coli O157:H7 (Anonymous, 1995; Banatvala et al., 1996;
Tarr et al., 1996; Fey et al., 2000; Brooks et al., 2004). It is estimated
that 96,534 infections are caused by E. coli O157:H7, annually in the
United States while non-O157 STECs serotypes cause 168,698 infections
(Scallan et al., 2011). Approximately 20–50% of worldwide STEC infec-
tions are caused by non-O157 serotypes; incidence varies depending
on geographical topology as well as climate conditions (Johnson et al.,
2006; Nataro and Kaper, 1998) Cattle represent the prime reservoir of
STEC strains, exhibiting a particularly high prevalence of non-O157
STEC strains (Bettelheim, 2001). The top six non-O157 STEC serogroups
most commonly implicated in illnesses are O26, O111, O103, O121, O45,
and O145 (Atkinson et al., 2006; Brooks et al., 2005; Gyles, 2006). STECs
causes human illness by expressing at least one Shiga toxin gene (Stx)
consisting of two forms; Stx1 and Stx2. Between these two isoforms,
Stx2 exhibits higher virulence. Its variants are associated with an en-
hanced probability of HC and HUS (Beutin et al., 2008). Not all
non-O157 STECs will cause human illness, therefore developing a
rapid and highly sensitive method for identification of non-O157 STEC
capable of pathogenesis would be of great benefit for regulatory agen-
cies as well as in clinical medicine (Bettelheim, 2007).
We have developed a 7-plexmicrobead-based immunoassay to allow
simultaneous serotyping of STEC strains belonging to serogroups O26,
O45, O103, O111, O121, O145, and O157 by the Luminex xMAP® tech-
nology. Polyclonal antibodies that bind each bacterial serogroup were
conjugated to microbeads used by the Luminex platform, thus allowing
the identification of specific pathogenic bacteria.We tested the specificity
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of our 7-plex microbead-based immunoassay against a collection of 79
PCR typed E. coli strains belonging to the top 7 E. coli. Such an immunoas-
say presents significant advantages. The 96-well format allows high
throughput, while the multiplexed format (up to 100 analytes) saves
time, reagents, and test samples. Conventional serotyping methods for
identification of non-O157 STECs are reliable forms of classification, but
can be laborious as well as time consuming often requiring skilled tech-
nicians having access to sufficient high quality H antisera, which are
mostly available in a few reference laboratories worldwide (Machado
et al., 2000). Many affiliated Food Safety and Inspection Service (FSIS),
Food and Drug Administration (FDA), and Food Emergency Response
Network (FERN) laboratories currently utilize the Luminex platform for
other assays, and our immunoassay would be directly transferable and
could be implemented by these laboratories.
2. Materials and methods
2.1. Antibodies
The antibodies used in this study were previously described
(Olsson-Allen et al., 2011; Hegde et al., 2012). These were prepared
and purified by SDIX using proprietary methods. Several antibodies
(goat anti-E. coli O26, O45, O103, O111, O121, O145, and O157; rabbit
anti-E. coli O26, O45, O103, O111, O121, O145, and O157; and mouse
anti-E. coli O157) were screened against one representative strain of
each serogroup by indirect then by microplate sandwich ELISA, using
a checkerboard strategy to determine the optimized concentrations of
both capture and detector antibodies (data not shown). Except for
O45, O145 and O157, the capture antibodies with the highest signal to
noise ratio were from goats (data not shown). The best capture anti-
bodies for O45 and O145 were from rabbit samples, and the ones cho-
sen for O157 were of murine origin. Except for the capture antibodies
for O157whichwere used at a concentration of 50 μg/mL, all antibodies
were used at a concentration of 5 μg/mL. Except for O157, the same an-
tibodies were used for both capture and detection. The best detection
antibodies for O157 were from goat samples. All detection antibodies
were used at concentrations of 1 μg/mL. Detector antibodies were
biotinylated with the EZ-Link Sulfo-NHS-Long Chain-Biotin kit (Pierce,
Rockford, IL), according to the manufacturer's instructions.
2.2. Analytes
E. coli strains (Table 1) were inoculated in 5 mL of brain heart infu-
sion broth (BHIB; Oxoid, Ltd., Basingstoke, UK). Sampleswere then incu-
bated overnight (15 h) in a shaking incubator (100 rpm) at 37 °C. After
enrichment, the samples were diluted to an OD600 of 0.01 in PBS
(pH 7.4). Sampleswere tested by our 7-plexmicrobead-based immuno-
assay using the Luminex xMAP® technology (q.v.). The STEC strains
used in this study were human and environmental isolates including
the seven serogroups more commonly associated with outbreak of
human illnesses. The serogroups of the strains used were previously
confirmed by PCR (Lin et al., 2011). Appropriate Biosafety Level 2 pre-
cautions were used when handling pathogenic E. coli organisms.
2.3. Buffers and reagents
Phosphate-buffered saline (PBS)with a pHof 7.4was used to prepare
PBS-TB (PBS, 0.02% Tween 20, and 1% bovine serum albumin) and PBS-T
(PBS and 0.1% Tween 20) that were used for washes. Reagent-grade
chemicals (i.e., 2,29-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)
[ABTS], H2O2, KCl, Na3 citrate, NaCl, and Tween 20) were purchased
from Sigma Chemical Co. (St Louis, MO); immunoglobulin (Ig) G-free,
protease-free bovine serum albumin from Jackson ImmunoResearch
(West Grove, PA); streptavidin labeled with R-phycoerythrin from
Invitrogen (Carlsbad, CA); and streptavidin-horseradish peroxidase con-
jugate from Zymed (San Francisco, CA).
2.4. Indirect ELISA assay protocol
A representative strain of each E. coli serogroup was diluted to an
OD600 of 0.01 in PBS (pH 7.4). The wells of a 96-well plate (Nunc,
Rochester, NY) were coated with 100 μL of the diluted bacteria and in-
cubated overnight at 4 °C. After removing the bacterial solution, the
plates were washed three times with PBS-T and blocked with 200 μL
of PBS-TB for 1 h at room temperature. After three washes with PBS-T,
100 μL of antibody solutions was added to the plate and incubated for
1 h at room temperature. After three washes with PBS-T, 100 μL of a
1/500 dilution of HRP-conjugated goat anti-rabbit, rabbit anti-goat, or
rabbit anti-mouse polyclonal was added to each well and incubated
for 1 h at room temperature. After three washes with PBS-T, 100 μL of
ABTS (2,29-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid; Sigma
Chemical Co., St Louis, MO)-horseradish peroxidase substrate solution
(Zymed, San Francisco, CA)) was added to each well to detect bound,
conjugated antibodies. This substrate solution (pH 4.2) was made of
0.548 g/L of ABTS and 17.64 g/L of sodium citrate (Sigma Chemical
Co.). A total of 40 μL of 1 MH2O2was then added to 6 mL of ABTS citrate.
After 15 min of incubation at room temperature, absorbancewas read at
405 nm with theWallac Victor 2 Multilabel Counter (PerkinElmer, Inc.,
Waltham, MA).
2.5. Sandwich ELISA assay protocol
Selected antibodieswere previously tested by sandwich ELISA to op-
timize the assay conditions (i.e., concentrations of capture and detector
antibodies) prior to incorporating those into a 7-plex microbead-based
immunoassay on the Luminex platform for further specificity testing
Table 1
STEC strains tested by the 7-plex microbead-based immunoassay.
O
serogroup
Strain
identification
O
serogroup
Strain
identification
O
serogroup
Strain
identification
O26 H19a O111 CL-37a O157 5343c
DEC10Ba DEC8Ba 5354c
DEC10Ca 3007-85a 5618c
DEC9Fa TB226Aa 5718c
TB285Ca 928/91a 6411c
VP30a 412/55a 6418c
TB285Aa DEC8Ca 6448c
TB352Aa C412a 6515c
EK29a BCL19a 6577c
97-3250a ED-31a 6613c
O45 TWO7947a BCL17a 6633c
B8026-C1a EK35a 6646c
B8227-C8a 3215-99a
08-00017b DA-18a
D88-28058a 88-4110Ha
DEC11Ca O121 DA-69a
5431-72a MT42a
4309-65a 3-524a
2566-58a F6173a
B8227-C8a DA-1a
O103 TB154Aa DA-5a
87-2931a DA-37a
MT#82a MT#2a
MT#80a 87-2914a
EK30a MT#11a
EK31a MT#22a
EK32a O145 GS-G5578620a
109-494a IHIT0304a
107-226a TB269Ca
PMK5a MT#66a
RW1372a BCL73a
RW1374a IH 16a
DA40a 02-3422a
D55a
a Strains obtained from the STEC center at Michigan State University's National Food
Safety and Toxicology Center, East Lansing, MI.
b Strain obtained from the Ohio State Department of Agriculture, Reynoldsburg, OH.
c Strains obtained from the Orange County Public Health Laboratory, Santa Ana, CA.
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(Bernard et al., 2012). A checkerboard analysis was conducted to assess
which concentrations of capture and detector antibodies worked best.
One hundredmicroliters of a solution in PBS (pH 7.4) of capture an-
tibodies (i.e., ranging from 0.5 to 2.0 μg/mL)was added to eachwell of a
96-well plate (Nunc, Rochester, NY) and incubated overnight at 4 °C.
After removing the capture antibody solution, the plates were then
blocked with 200 μL of PBS-TB for 1 h at room temperature. After
three washes with PBS-T, 100 μL of analyte solutions was added to the
plate and incubated for 1 h at room temperature. After three washes
with PBS-T, 100 μL of a 0.5-mg/mL solution in PBS pH 7.4 of detector
antibody (i.e., ranging from 0.125 to 2.0 μg/mL) was added to each
well and incubated for 1 h at room temperature. After three washes
with PBS-T, 100 μL of a 1/5000 dilution of streptavidin-horseradish per-
oxidase conjugate in PBS-TB was added to each well and incubated for
1 h at room temperature. After three washes with PBS-T, 100 μL of
ABTS-horseradish peroxidase substrate solution was added to each
well to detect bound, conjugated antibody. After 15 min of incubation
at room temperature, absorbance was read at 405 nm with the Wallac
Victor 2Multilabel Counter (PerkinElmer, Inc.,Waltham,MA). The opti-
mal antigen, capture, and detector antibody concentrations were deter-
mined by serial dilutions. For all the pairs of antibodies tested, using the
capture antibodies at a concentration of 1 μg/mL and detector anti-
bodies at a concentration of 0.5 μg/mL worked best (data not shown).
2.6. Covalent coupling of antibodies to carboxylated magnetic
Seven different sets of spectrally unique carboxylated Magplex
superparamagnetic microbeads (6.5 mm in diameter; Luminex Corp.,
Austin, TX) were coated with capture antibodies according to the
manufacturer's instructions providedwith the Bio-Plex Amine Coupling
Kit (Bio-Rad, Hercules, CA). Bead region numbers 35, 51, 52, 53, 54, 55,
and 56 were used to couple the capture antibodies for O157, O26, O45,
O103, O111, O121, and O145, respectively. Briefly, each antibody was
covalently coupled to a unique set of microbeads (1.25×106 beads
per 100 μL coupling reaction) in a two-step carbodiimide-coupling
protocol that utilized 50 mg/mL N-hydroxysulfosuccinimide sodium
salt (Pierce Chemicals, Rockford, IL) and 50 mg/mL 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (Pierce Chemicals).
After each reaction, the concentration of themicrobead suspension was
determined by a hemacytometer, and the coupledmicrobeads stored at
2 to 8 °C in the dark. Each coupling reaction was confirmed with
phycoerythrin-labeled specie anti-species IgG antibodies (Invitrogen)
at concentrations ranging from 0.5 to 32 μg/mL (Fig. 1).
2.7. 7-Plex microbead-based immunoassay protocol
The 7-plex microbead-based immunoassays were conducted in
black, 96-well round bottom polystyrene microplates (Corning Costar,
Lowell, MA), according to Luminex protocols (www.luminexcorp.
com). All incubations were for 1 h at room temperature, protected
from light, and shaken at 600 rpm. In brief, a 100-μl aliquot of each
test sample (bacteria diluted in PBS to OD600 0.01) was combined with
5000 microbeads (previously blocked for 30 min in PBS-TB) of each of
the seven specificities: E. coli O26, O45, O103, O111, O121, O145, and
O157 in a single microplate well. The microbeads were washed from
unbound reaction components three times with PBS-TB using the Bio-
Plex Pro Wash Station (Bio-Rad). Microbeads were then resuspended
in 100 μL of the biotinylated detector antibody cocktail, containing
1 μg/mL of each antibody and the resultant mixture was incubated.
The mixture was then washed three times as described earlier,
resuspended in 100 μL of 4 μg/mL streptavidin labeled with R-
phycoerythrin, and the resultant mixture was incubated, washed, and
resuspended in 100 μL of PBS. The samples were analyzed by Bio-Plex
Manager 6.0 standard software (Bio-Rad) with the Luminex 100 flow
analyzer. Data were acquired using the following settings: 50 μL sample
volume, 100 beads per region, 120 s reading, and DD gate 5000–25,000.
The background fluorescence (i.e., blank samples) was measured on
samples containing all immunoassay reagents except the analyte(s) of
interest. In fact, every microbead has an inherent fluorescence because
of the two fluorochromes embedded in each microbead.
2.8. Statistical analysis
For statistical analysis, the threshold for a positive result was de-
fined as a net Median Fluorescent Intensity (MFI) value that was at
least three times greater than the background MFI.
3. Results
3.1. Antibody coupling to microbeads
Once conditionswere optimized by sandwich ELISA, the surface area
of a microplate well was compared to the surface area of a microbead in
order to calculate the amount of capture antibodies necessary for cou-
pling. After coupling we used PE-labeled anti-species antibodies (in a
single-plex format) to confirm that the antibodies had been coupled to
the microbeads successfully. In this immunoassay, the background
wells contained the beads, but not the anti-species-PE (i.e., MFIb30).
In Fig. 1, the high MFI values, ranging from 15,338 for O157 to 23,532.5
for O26, indicated that the antibodies were successfully coupled to the
beads.
3.2. 7-Plex microbead-based immunoassay specificity
The specificity of the 7-plex microbead-based immunoassay was
tested by examining 79 STEC strains listed in Table 1, representing
the seven O serogroups included in the assay. The resulting signal to
background ratios is shown in Table 2 with positive samples and stan-
dard deviations indicated in bold. Except for one strain belonging to
the O111 serogroup (i.e., BCL-19), all others were correctly identified.
Thus the recovery of STEC by our newly developed 7-plex
microbead-based immunoassay was 98.7%.
4. Discussion
A recent study by Verstraete et al. (2012) evaluated amethod for the
isolation of non-O157 STEC and sorbitol fermenting (SF) E. coli O157 in
food (Possé et al., 2008), where samples were also submitted to a
rapid predictive screening test for virulence genes (stx, eae, and ehxA
[enterohemolysin]). The non-O157 STEC serotypes studied included
O26, O103, O111, O145, non-sorbitol fermenting (NSF) O157, and SF
O157. Food enrichments (i.e., minced beef, raw-milk cheese, and
sprouted seeds) were inoculated with low numbers of bacterial cells of
above mentioned serotypes. Bacterial cells were either non-stressed,
cold stressed or freeze stressed. Of the analyzed serotypes only O111
and SF O157 strains resulted in an increased number of false negatives.
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Fig. 1. Confirmation of antibody coupling to the Luminex microbeads using phycoery-
thrin (PE)-labeled anti-species.
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The false negatives could possibly be due to the stressed state of cells.
Typically, stressed cells endure a longer lag-phase before exponential
growth takes place (Jasson et al., 2007), therefore resulting in decreased
growth in broth culture after an overnight incubation. In addition it is
possible that certain serotypes grow more efficiently in some broths
than others, and selective components may reduce the growth of target
strains, as could be the case for O111 serogroup (Verstraete et al., 2012).
Classification of bacteria is typically done in terms of repeating
chains of their O-antigen, capsular composition, and flagella antigens
(Hitchcock et al., 1986). An important observation is that serotype clas-
sification involves the type, but not the number, of repeating O-antigen
units. This allows for a level of enhanced variationwithin a strain of bac-
teria (Strauss et al., 2009). Strauss et al. (2009) conducted a study in
which 5 E. coli strains that expressed O-antigen were compared to one
another in terms of LPS length by atomic force microscopy. The strains
compared in this study were E. coli O113:H4, O113:H21, O157:H7,
O157:H12, and O157:H16. Out of these strains O113:H21 demonstrated
a significantly greater LPS length compared to all other strains while
O157:H7 exhibited the second greatest LPS length. This indicates that
O-antigen exhibits great variability, and suggests a means for enhanced
attachment of E. coli O113 and O157 to human intestinal cells and food
surfaces, such as fresh produce (Manges et al., 2001). Such variation also
explainswhy theMFI signals in our assay vary from strain to strain, even
among a single serogroup.
Future directions include transferring the assay to the new, portable
MagPix system. This would ultimately give us a portable, reproducible,
and very sensitive assay that is capable of serotyping the top 7 E. coli.
We also plan on developing monoclonal antibodies for those targets,
and addingmore antibodies to our 7-plexmicrobead-based immunoas-
say such as E. coliO91, O104, andO113 aswell as other outermembrane
proteins eliciting pathogenicity by adhering bacteria onto intestinal ep-
ithelial cells. Ultimately we would like to perform ourmicrobead-based
immunoassay on the KingFisher automated high throughput platform
and test it in food enrichments.
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